Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06005792 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
A Phase 1 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT06005792 is a Phase 1 study that was terminated before completion, run by Xencor. The registered enrollment target is 23 participants.
The verdict
NCT06005792, a Phase 1 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL XmAb27564
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2024-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06005792
The ClinicalTrials.gov registry entry for NCT06005792 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06005792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06005792 about?
NCT06005792 is a clinical study titled "Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis". The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.
What is the current status of trial NCT06005792?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2022-10-10. Estimated completion is 2024-11-22.
What interventions are being tested in trial NCT06005792?
The interventions under investigation include: Placebo (BIOLOGICAL), XmAb27564 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06005792?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.